Oligonucleotide (Antisense oligonucleotide) · Gene silencing: angiotensinogen (AGT) · developed by IONIS PHARMACEUTICALS
IONIS-AGT-LRx is an antisense oligonucleotide that reduces angiotensinogen (AGT) production. It is administered by subcutaneous injection and is being studied in hypertension.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04714320 | Phase 2 | Hypertension | Completed | IONS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hypertension
Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.
See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IONS catalysts and pipeline →